Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism

被引：0
|
作者：
Hui-Yan Shi
Jin Yan
Wen-Hui Zhu
Guo-Ping Yang
Zhi-Rong Tan
Wei-Hua Wu
Gan Zhou
Xiao-Ping Chen
Dong-Sheng Ouyang
机构：
[1] Central South University,Pharmacogenetics Research Institute, Institute of Clinical Pharmacology
[2] Central South University,Third Xiangya Hospital
[3] Central South University,Department of Pharmacology, School of Pharmaceutical Science
来源：
European Journal of Clinical Pharmacology | 2010年 / 66卷
关键词：
Voriconazole; Erythromycin; CYP2C19; Genetic polymorphism; Chinese;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1131 / 1136
页数：5
相关论文
共 50 条
  • [31] Pharmacogenetic implementation for CYP2C19 and pharmacokinetics of voriconazole in children with malignancy or inborn errors of immunity
    Shoji, Kensuke
    Hikino, Keiko
    Saito, Jumpei
    Matsui, Toshihiro
    Utano, Tomoyuki
    Takebayashi, Akira
    Tomizawa, Daisuke
    Kato, Motohiro
    Matsumoto, Kimikazu
    Ishikawa, Takashi
    Kawai, Toshinao
    Nakamura, Hidefumi
    Miyairi, Isao
    Terao, Chikashi
    Mushiroda, Taisei
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2024, 30 (12) : 1280 - 1288
  • [32] Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype
    Scholz, Ina
    Oberwittler, Heike
    Riedel, Klaus-Dieter
    Burhenne, Juergen
    Weiss, Johanna
    Haefeli, Walter E.
    Mikus, Gerd
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (06) : 906 - 915
  • [33] Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients
    Li, Zi-Wei
    Peng, Feng-Hua
    Yan, Miao
    Liang, Wu
    Liu, Xiao-Lei
    Wu, Yan-Qin
    Lin, Xiao-Bin
    Tan, Sheng-Lan
    Wang, Feng
    Xu, Ping
    Fang, Ping-Fei
    Liu, Yi-Ping
    Xiang, Da-Xiong
    Zhang, Bi-Kui
    THERAPEUTIC DRUG MONITORING, 2017, 39 (04) : 422 - 428
  • [34] Population pharmacokinetics of voriconazole and the role of CYP2C19 genotype on treatment optimization in pediatric patients
    Hu, Lin
    Huang, Shiqiong
    Huang, Qi
    Huang, Juanjuan
    Feng, Zeying
    He, Gefei
    PLOS ONE, 2023, 18 (09):
  • [35] Association between CYP2C19 genotype and proguanil oxidative polymorphism
    Coller, JK
    Somogyi, AA
    Bochner, F
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 43 (06) : 659 - 660
  • [36] A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles
    Chung, Hyewon
    Lee, Howard
    Han, HyeKyung
    An, Hyungmi
    Lim, Kyoung Soo
    Lee, YongJin
    Cho, Joo-Youn
    Yoon, Seo Hyun
    Jang, In-Jin
    Yu, Kyung-Sang
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 2609 - 2616
  • [37] CYP2C19*17 genetic polymorphism-an uncommon cause of voriconazole treatment failure
    Abidi, Maheen Z.
    D'Souza, Anita
    Kuppalli, Krutika
    Ledeboer, Nathan
    Hari, Parmeswaran
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2015, 83 (01) : 46 - 48
  • [38] Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole
    Klomp, Sylvia D.
    Veringa, Anette
    Alffenaar, Jan-Willem C.
    de Boer, Mark G. J.
    Span, Lambert F. R.
    Guchelaar, Henk-Jan
    Swen, Jesse J.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (07):
  • [39] CYP2C19 GENETIC POLYMORPHISM HAS SIGNIFICANT EFFECTS ON THE PHARMACOKINETICS OF TOLPERISONE AFTER ADMINISTRATION OF FLUOXETINE
    Kim, S. H.
    Byeon, J. Y.
    Kim, Y. H.
    Lee, H. J.
    Lee, Y.
    Lee, Y. J.
    Kim, D. H.
    Lim, H. J.
    Lee, S. Y.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E60 - E60
  • [40] Effect of CYP2C19 polymorphism on the plasma voriconazole concentration and voriconazole-to-voriconazole-N-oxide concentration ratio in elderly patients
    Shang, Shenglan
    Cheng, Lin
    Li, Xiaoyu
    Xiang, Rongfeng
    Yu, Mingjie
    Xiong, Lirong
    Chen, Yongchuan
    MYCOSES, 2020, 63 (11) : 1181 - 1190
12345